Global Antibody-radionuclide Conjugates Market Growth (Status and Outlook) 2026-2032
The global Antibody-radionuclide Conjugates market size is predicted to grow from US$ 2236 million in 2025 to US$ 7011 million in 2032; it is expected to grow at a CAGR of 18.1% from 2026 to 2032.
Antibody-radionuclide Conjugates is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The Antibody-radionuclide Conjugates Market is driven by the increasing interest in targeted cancer therapy and the potential of combining monoclonal antibodies with radioactive isotopes to deliver precise treatment. Antibody-radionuclide conjugates offer a highly focused approach to treating cancer by delivering radiation directly to tumor cells, minimizing damage to healthy tissue. As the understanding of cancer biology and immunotherapy advances, and personalized treatment options gain prominence, the demand for these conjugates continues to grow. Innovations in conjugation techniques, radiolabeling methods, and the expansion of the oncology pipeline further contribute to market expansion. However, a significant challenge for this market is the need to address complex drug development processes, optimize safety and efficacy, and navigate regulatory standards while ensuring affordability and accessibility for patients. Overcoming production challenges, minimizing off-target effects, and managing development costs are ongoing hurdles. Additionally, the market faces competition from other cancer therapies and the need for continuous research and development to enhance the efficiency and precision of antibody-radionuclide conjugates. Striking a balance between providing safe, effective, and accessible targeted cancer treatments while addressing scientific and regulatory challenges is essential for the continued growth of the Antibody-radionuclide Conjugates Market.
LPI (LP Information)' newest research report, the “Antibody-radionuclide Conjugates Industry Forecast” looks at past sales and reviews total world Antibody-radionuclide Conjugates sales in 2025, providing a comprehensive analysis by region and market sector of projected Antibody-radionuclide Conjugates sales for 2026 through 2032. With Antibody-radionuclide Conjugates sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-radionuclide Conjugates industry.
This Insight Report provides a comprehensive analysis of the global Antibody-radionuclide Conjugates landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody-radionuclide Conjugates portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody-radionuclide Conjugates market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-radionuclide Conjugates and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-radionuclide Conjugates.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-radionuclide Conjugates market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antibody-radionuclide Conjugates is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The Antibody-radionuclide Conjugates Market is driven by the increasing interest in targeted cancer therapy and the potential of combining monoclonal antibodies with radioactive isotopes to deliver precise treatment. Antibody-radionuclide conjugates offer a highly focused approach to treating cancer by delivering radiation directly to tumor cells, minimizing damage to healthy tissue. As the understanding of cancer biology and immunotherapy advances, and personalized treatment options gain prominence, the demand for these conjugates continues to grow. Innovations in conjugation techniques, radiolabeling methods, and the expansion of the oncology pipeline further contribute to market expansion. However, a significant challenge for this market is the need to address complex drug development processes, optimize safety and efficacy, and navigate regulatory standards while ensuring affordability and accessibility for patients. Overcoming production challenges, minimizing off-target effects, and managing development costs are ongoing hurdles. Additionally, the market faces competition from other cancer therapies and the need for continuous research and development to enhance the efficiency and precision of antibody-radionuclide conjugates. Striking a balance between providing safe, effective, and accessible targeted cancer treatments while addressing scientific and regulatory challenges is essential for the continued growth of the Antibody-radionuclide Conjugates Market.
LPI (LP Information)' newest research report, the “Antibody-radionuclide Conjugates Industry Forecast” looks at past sales and reviews total world Antibody-radionuclide Conjugates sales in 2025, providing a comprehensive analysis by region and market sector of projected Antibody-radionuclide Conjugates sales for 2026 through 2032. With Antibody-radionuclide Conjugates sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-radionuclide Conjugates industry.
This Insight Report provides a comprehensive analysis of the global Antibody-radionuclide Conjugates landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody-radionuclide Conjugates portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody-radionuclide Conjugates market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-radionuclide Conjugates and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-radionuclide Conjugates.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-radionuclide Conjugates market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Beta-emitting
- Targeted Alpha Therapy
- Solid Tumor
- Non Hodgkin Lymphoma
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bayer
- Novartis
- Lantheus
- Aurobindo Pharma
- Mundipharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Gilead Sciences
- Clarity Pharmaceuticals
- Curasight
- Nordic Nanovector
- Philogen
- RadioMedix
- Telix Pharmaceuticals
- Orano Med
- Actinium Pharmaceuticals
- Y-mAbs Therapeutics
- Fusion Pharmaceuticals
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antibody-radionuclide Conjugates Market Size (2021-2032)
2.1.2 Antibody-radionuclide Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Antibody-radionuclide Conjugates by Country/Region (2021, 2025 & 2032)
2.2 Antibody-radionuclide Conjugates Segment by Type
2.2.1 Beta-emitting
2.2.2 Targeted Alpha Therapy
2.2.3 Antibody-radionuclide Conjugates Market Size by Type
2.2.3.1 Antibody-radionuclide Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
2.3 Antibody-radionuclide Conjugates Segment by Application
2.3.1 Solid Tumor
2.3.2 Non Hodgkin Lymphoma
2.3.3 Antibody-radionuclide Conjugates Market Size by Application
2.3.3.1 Antibody-radionuclide Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.3.2 Global Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
3 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET SIZE BY PLAYER
3.1 Antibody-radionuclide Conjugates Market Size Market Share by Player
3.1.1 Global Antibody-radionuclide Conjugates Revenue by Player (2021-2026)
3.1.2 Global Antibody-radionuclide Conjugates Revenue Market Share by Player (2021-2026)
3.2 Global Antibody-radionuclide Conjugates Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ANTIBODY-RADIONUCLIDE CONJUGATES BY REGION
4.1 Antibody-radionuclide Conjugates Market Size by Region (2021-2026)
4.2 Global Antibody-radionuclide Conjugates Annual Revenue by Country/Region (2021-2026)
4.3 Americas Antibody-radionuclide Conjugates Market Size Growth (2021-2026)
4.4 APAC Antibody-radionuclide Conjugates Market Size Growth (2021-2026)
4.5 Europe Antibody-radionuclide Conjugates Market Size Growth (2021-2026)
4.6 Middle East & Africa Antibody-radionuclide Conjugates Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Antibody-radionuclide Conjugates Market Size by Country (2021-2026)
5.2 Americas Antibody-radionuclide Conjugates Market Size by Type (2021-2026)
5.3 Americas Antibody-radionuclide Conjugates Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antibody-radionuclide Conjugates Market Size by Region (2021-2026)
6.2 APAC Antibody-radionuclide Conjugates Market Size by Type (2021-2026)
6.3 APAC Antibody-radionuclide Conjugates Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Antibody-radionuclide Conjugates Market Size by Country (2021-2026)
7.2 Europe Antibody-radionuclide Conjugates Market Size by Type (2021-2026)
7.3 Europe Antibody-radionuclide Conjugates Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antibody-radionuclide Conjugates by Region (2021-2026)
8.2 Middle East & Africa Antibody-radionuclide Conjugates Market Size by Type (2021-2026)
8.3 Middle East & Africa Antibody-radionuclide Conjugates Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ANTIBODY-RADIONUCLIDE CONJUGATES MARKET FORECAST
10.1 Global Antibody-radionuclide Conjugates Forecast by Region (2027-2032)
10.1.1 Global Antibody-radionuclide Conjugates Forecast by Region (2027-2032)
10.1.2 Americas Antibody-radionuclide Conjugates Forecast
10.1.3 APAC Antibody-radionuclide Conjugates Forecast
10.1.4 Europe Antibody-radionuclide Conjugates Forecast
10.1.5 Middle East & Africa Antibody-radionuclide Conjugates Forecast
10.2 Americas Antibody-radionuclide Conjugates Forecast by Country (2027-2032)
10.2.1 United States Market Antibody-radionuclide Conjugates Forecast
10.2.2 Canada Market Antibody-radionuclide Conjugates Forecast
10.2.3 Mexico Market Antibody-radionuclide Conjugates Forecast
10.2.4 Brazil Market Antibody-radionuclide Conjugates Forecast
10.3 APAC Antibody-radionuclide Conjugates Forecast by Region (2027-2032)
10.3.1 China Antibody-radionuclide Conjugates Market Forecast
10.3.2 Japan Market Antibody-radionuclide Conjugates Forecast
10.3.3 Korea Market Antibody-radionuclide Conjugates Forecast
10.3.4 Southeast Asia Market Antibody-radionuclide Conjugates Forecast
10.3.5 India Market Antibody-radionuclide Conjugates Forecast
10.3.6 Australia Market Antibody-radionuclide Conjugates Forecast
10.4 Europe Antibody-radionuclide Conjugates Forecast by Country (2027-2032)
10.4.1 Germany Market Antibody-radionuclide Conjugates Forecast
10.4.2 France Market Antibody-radionuclide Conjugates Forecast
10.4.3 UK Market Antibody-radionuclide Conjugates Forecast
10.4.4 Italy Market Antibody-radionuclide Conjugates Forecast
10.4.5 Russia Market Antibody-radionuclide Conjugates Forecast
10.5 Middle East & Africa Antibody-radionuclide Conjugates Forecast by Region (2027-2032)
10.5.1 Egypt Market Antibody-radionuclide Conjugates Forecast
10.5.2 South Africa Market Antibody-radionuclide Conjugates Forecast
10.5.3 Israel Market Antibody-radionuclide Conjugates Forecast
10.5.4 Turkey Market Antibody-radionuclide Conjugates Forecast
10.6 Global Antibody-radionuclide Conjugates Forecast by Type (2027-2032)
10.7 Global Antibody-radionuclide Conjugates Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Antibody-radionuclide Conjugates Forecast
11 KEY PLAYERS ANALYSIS
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Antibody-radionuclide Conjugates Product Offered
11.1.3 Bayer Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Antibody-radionuclide Conjugates Product Offered
11.2.3 Novartis Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Lantheus
11.3.1 Lantheus Company Information
11.3.2 Lantheus Antibody-radionuclide Conjugates Product Offered
11.3.3 Lantheus Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Lantheus Main Business Overview
11.3.5 Lantheus Latest Developments
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Information
11.4.2 Aurobindo Pharma Antibody-radionuclide Conjugates Product Offered
11.4.3 Aurobindo Pharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Aurobindo Pharma Main Business Overview
11.4.5 Aurobindo Pharma Latest Developments
11.5 Mundipharma
11.5.1 Mundipharma Company Information
11.5.2 Mundipharma Antibody-radionuclide Conjugates Product Offered
11.5.3 Mundipharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Mundipharma Main Business Overview
11.5.5 Mundipharma Latest Developments
11.6 China Isotope & Radiation
11.6.1 China Isotope & Radiation Company Information
11.6.2 China Isotope & Radiation Antibody-radionuclide Conjugates Product Offered
11.6.3 China Isotope & Radiation Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 China Isotope & Radiation Main Business Overview
11.6.5 China Isotope & Radiation Latest Developments
11.7 Curium Pharmaceuticals
11.7.1 Curium Pharmaceuticals Company Information
11.7.2 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
11.7.3 Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Curium Pharmaceuticals Main Business Overview
11.7.5 Curium Pharmaceuticals Latest Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Information
11.8.2 Gilead Sciences Antibody-radionuclide Conjugates Product Offered
11.8.3 Gilead Sciences Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Gilead Sciences Main Business Overview
11.8.5 Gilead Sciences Latest Developments
11.9 Clarity Pharmaceuticals
11.9.1 Clarity Pharmaceuticals Company Information
11.9.2 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
11.9.3 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Clarity Pharmaceuticals Main Business Overview
11.9.5 Clarity Pharmaceuticals Latest Developments
11.10 Curasight
11.10.1 Curasight Company Information
11.10.2 Curasight Antibody-radionuclide Conjugates Product Offered
11.10.3 Curasight Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Curasight Main Business Overview
11.10.5 Curasight Latest Developments
11.11 Nordic Nanovector
11.11.1 Nordic Nanovector Company Information
11.11.2 Nordic Nanovector Antibody-radionuclide Conjugates Product Offered
11.11.3 Nordic Nanovector Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Nordic Nanovector Main Business Overview
11.11.5 Nordic Nanovector Latest Developments
11.12 Philogen
11.12.1 Philogen Company Information
11.12.2 Philogen Antibody-radionuclide Conjugates Product Offered
11.12.3 Philogen Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Philogen Main Business Overview
11.12.5 Philogen Latest Developments
11.13 RadioMedix
11.13.1 RadioMedix Company Information
11.13.2 RadioMedix Antibody-radionuclide Conjugates Product Offered
11.13.3 RadioMedix Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 RadioMedix Main Business Overview
11.13.5 RadioMedix Latest Developments
11.14 Telix Pharmaceuticals
11.14.1 Telix Pharmaceuticals Company Information
11.14.2 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
11.14.3 Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Telix Pharmaceuticals Main Business Overview
11.14.5 Telix Pharmaceuticals Latest Developments
11.15 Orano Med
11.15.1 Orano Med Company Information
11.15.2 Orano Med Antibody-radionuclide Conjugates Product Offered
11.15.3 Orano Med Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Orano Med Main Business Overview
11.15.5 Orano Med Latest Developments
11.16 Actinium Pharmaceuticals
11.16.1 Actinium Pharmaceuticals Company Information
11.16.2 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
11.16.3 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Actinium Pharmaceuticals Main Business Overview
11.16.5 Actinium Pharmaceuticals Latest Developments
11.17 Y-mAbs Therapeutics
11.17.1 Y-mAbs Therapeutics Company Information
11.17.2 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Offered
11.17.3 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Y-mAbs Therapeutics Main Business Overview
11.17.5 Y-mAbs Therapeutics Latest Developments
11.18 Fusion Pharmaceuticals
11.18.1 Fusion Pharmaceuticals Company Information
11.18.2 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
11.18.3 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Fusion Pharmaceuticals Main Business Overview
11.18.5 Fusion Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antibody-radionuclide Conjugates Market Size (2021-2032)
2.1.2 Antibody-radionuclide Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Antibody-radionuclide Conjugates by Country/Region (2021, 2025 & 2032)
2.2 Antibody-radionuclide Conjugates Segment by Type
2.2.1 Beta-emitting
2.2.2 Targeted Alpha Therapy
2.2.3 Antibody-radionuclide Conjugates Market Size by Type
2.2.3.1 Antibody-radionuclide Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
2.3 Antibody-radionuclide Conjugates Segment by Application
2.3.1 Solid Tumor
2.3.2 Non Hodgkin Lymphoma
2.3.3 Antibody-radionuclide Conjugates Market Size by Application
2.3.3.1 Antibody-radionuclide Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.3.2 Global Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
3 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET SIZE BY PLAYER
3.1 Antibody-radionuclide Conjugates Market Size Market Share by Player
3.1.1 Global Antibody-radionuclide Conjugates Revenue by Player (2021-2026)
3.1.2 Global Antibody-radionuclide Conjugates Revenue Market Share by Player (2021-2026)
3.2 Global Antibody-radionuclide Conjugates Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ANTIBODY-RADIONUCLIDE CONJUGATES BY REGION
4.1 Antibody-radionuclide Conjugates Market Size by Region (2021-2026)
4.2 Global Antibody-radionuclide Conjugates Annual Revenue by Country/Region (2021-2026)
4.3 Americas Antibody-radionuclide Conjugates Market Size Growth (2021-2026)
4.4 APAC Antibody-radionuclide Conjugates Market Size Growth (2021-2026)
4.5 Europe Antibody-radionuclide Conjugates Market Size Growth (2021-2026)
4.6 Middle East & Africa Antibody-radionuclide Conjugates Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Antibody-radionuclide Conjugates Market Size by Country (2021-2026)
5.2 Americas Antibody-radionuclide Conjugates Market Size by Type (2021-2026)
5.3 Americas Antibody-radionuclide Conjugates Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antibody-radionuclide Conjugates Market Size by Region (2021-2026)
6.2 APAC Antibody-radionuclide Conjugates Market Size by Type (2021-2026)
6.3 APAC Antibody-radionuclide Conjugates Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Antibody-radionuclide Conjugates Market Size by Country (2021-2026)
7.2 Europe Antibody-radionuclide Conjugates Market Size by Type (2021-2026)
7.3 Europe Antibody-radionuclide Conjugates Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antibody-radionuclide Conjugates by Region (2021-2026)
8.2 Middle East & Africa Antibody-radionuclide Conjugates Market Size by Type (2021-2026)
8.3 Middle East & Africa Antibody-radionuclide Conjugates Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ANTIBODY-RADIONUCLIDE CONJUGATES MARKET FORECAST
10.1 Global Antibody-radionuclide Conjugates Forecast by Region (2027-2032)
10.1.1 Global Antibody-radionuclide Conjugates Forecast by Region (2027-2032)
10.1.2 Americas Antibody-radionuclide Conjugates Forecast
10.1.3 APAC Antibody-radionuclide Conjugates Forecast
10.1.4 Europe Antibody-radionuclide Conjugates Forecast
10.1.5 Middle East & Africa Antibody-radionuclide Conjugates Forecast
10.2 Americas Antibody-radionuclide Conjugates Forecast by Country (2027-2032)
10.2.1 United States Market Antibody-radionuclide Conjugates Forecast
10.2.2 Canada Market Antibody-radionuclide Conjugates Forecast
10.2.3 Mexico Market Antibody-radionuclide Conjugates Forecast
10.2.4 Brazil Market Antibody-radionuclide Conjugates Forecast
10.3 APAC Antibody-radionuclide Conjugates Forecast by Region (2027-2032)
10.3.1 China Antibody-radionuclide Conjugates Market Forecast
10.3.2 Japan Market Antibody-radionuclide Conjugates Forecast
10.3.3 Korea Market Antibody-radionuclide Conjugates Forecast
10.3.4 Southeast Asia Market Antibody-radionuclide Conjugates Forecast
10.3.5 India Market Antibody-radionuclide Conjugates Forecast
10.3.6 Australia Market Antibody-radionuclide Conjugates Forecast
10.4 Europe Antibody-radionuclide Conjugates Forecast by Country (2027-2032)
10.4.1 Germany Market Antibody-radionuclide Conjugates Forecast
10.4.2 France Market Antibody-radionuclide Conjugates Forecast
10.4.3 UK Market Antibody-radionuclide Conjugates Forecast
10.4.4 Italy Market Antibody-radionuclide Conjugates Forecast
10.4.5 Russia Market Antibody-radionuclide Conjugates Forecast
10.5 Middle East & Africa Antibody-radionuclide Conjugates Forecast by Region (2027-2032)
10.5.1 Egypt Market Antibody-radionuclide Conjugates Forecast
10.5.2 South Africa Market Antibody-radionuclide Conjugates Forecast
10.5.3 Israel Market Antibody-radionuclide Conjugates Forecast
10.5.4 Turkey Market Antibody-radionuclide Conjugates Forecast
10.6 Global Antibody-radionuclide Conjugates Forecast by Type (2027-2032)
10.7 Global Antibody-radionuclide Conjugates Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Antibody-radionuclide Conjugates Forecast
11 KEY PLAYERS ANALYSIS
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Antibody-radionuclide Conjugates Product Offered
11.1.3 Bayer Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Antibody-radionuclide Conjugates Product Offered
11.2.3 Novartis Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Lantheus
11.3.1 Lantheus Company Information
11.3.2 Lantheus Antibody-radionuclide Conjugates Product Offered
11.3.3 Lantheus Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Lantheus Main Business Overview
11.3.5 Lantheus Latest Developments
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Information
11.4.2 Aurobindo Pharma Antibody-radionuclide Conjugates Product Offered
11.4.3 Aurobindo Pharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Aurobindo Pharma Main Business Overview
11.4.5 Aurobindo Pharma Latest Developments
11.5 Mundipharma
11.5.1 Mundipharma Company Information
11.5.2 Mundipharma Antibody-radionuclide Conjugates Product Offered
11.5.3 Mundipharma Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Mundipharma Main Business Overview
11.5.5 Mundipharma Latest Developments
11.6 China Isotope & Radiation
11.6.1 China Isotope & Radiation Company Information
11.6.2 China Isotope & Radiation Antibody-radionuclide Conjugates Product Offered
11.6.3 China Isotope & Radiation Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 China Isotope & Radiation Main Business Overview
11.6.5 China Isotope & Radiation Latest Developments
11.7 Curium Pharmaceuticals
11.7.1 Curium Pharmaceuticals Company Information
11.7.2 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
11.7.3 Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Curium Pharmaceuticals Main Business Overview
11.7.5 Curium Pharmaceuticals Latest Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Information
11.8.2 Gilead Sciences Antibody-radionuclide Conjugates Product Offered
11.8.3 Gilead Sciences Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Gilead Sciences Main Business Overview
11.8.5 Gilead Sciences Latest Developments
11.9 Clarity Pharmaceuticals
11.9.1 Clarity Pharmaceuticals Company Information
11.9.2 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
11.9.3 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Clarity Pharmaceuticals Main Business Overview
11.9.5 Clarity Pharmaceuticals Latest Developments
11.10 Curasight
11.10.1 Curasight Company Information
11.10.2 Curasight Antibody-radionuclide Conjugates Product Offered
11.10.3 Curasight Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Curasight Main Business Overview
11.10.5 Curasight Latest Developments
11.11 Nordic Nanovector
11.11.1 Nordic Nanovector Company Information
11.11.2 Nordic Nanovector Antibody-radionuclide Conjugates Product Offered
11.11.3 Nordic Nanovector Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Nordic Nanovector Main Business Overview
11.11.5 Nordic Nanovector Latest Developments
11.12 Philogen
11.12.1 Philogen Company Information
11.12.2 Philogen Antibody-radionuclide Conjugates Product Offered
11.12.3 Philogen Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Philogen Main Business Overview
11.12.5 Philogen Latest Developments
11.13 RadioMedix
11.13.1 RadioMedix Company Information
11.13.2 RadioMedix Antibody-radionuclide Conjugates Product Offered
11.13.3 RadioMedix Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 RadioMedix Main Business Overview
11.13.5 RadioMedix Latest Developments
11.14 Telix Pharmaceuticals
11.14.1 Telix Pharmaceuticals Company Information
11.14.2 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
11.14.3 Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Telix Pharmaceuticals Main Business Overview
11.14.5 Telix Pharmaceuticals Latest Developments
11.15 Orano Med
11.15.1 Orano Med Company Information
11.15.2 Orano Med Antibody-radionuclide Conjugates Product Offered
11.15.3 Orano Med Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Orano Med Main Business Overview
11.15.5 Orano Med Latest Developments
11.16 Actinium Pharmaceuticals
11.16.1 Actinium Pharmaceuticals Company Information
11.16.2 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
11.16.3 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Actinium Pharmaceuticals Main Business Overview
11.16.5 Actinium Pharmaceuticals Latest Developments
11.17 Y-mAbs Therapeutics
11.17.1 Y-mAbs Therapeutics Company Information
11.17.2 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Offered
11.17.3 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Y-mAbs Therapeutics Main Business Overview
11.17.5 Y-mAbs Therapeutics Latest Developments
11.18 Fusion Pharmaceuticals
11.18.1 Fusion Pharmaceuticals Company Information
11.18.2 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
11.18.3 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Fusion Pharmaceuticals Main Business Overview
11.18.5 Fusion Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Antibody-radionuclide Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Antibody-radionuclide Conjugates Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Beta-emitting
Table 4. Major Players of Targeted Alpha Therapy
Table 5. Antibody-radionuclide Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Antibody-radionuclide Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
Table 8. Antibody-radionuclide Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Antibody-radionuclide Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
Table 11. Global Antibody-radionuclide Conjugates Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Antibody-radionuclide Conjugates Revenue Market Share by Player (2021-2026)
Table 13. Antibody-radionuclide Conjugates Key Players Head office and Products Offered
Table 14. Antibody-radionuclide Conjugates Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Antibody-radionuclide Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Antibody-radionuclide Conjugates Market Size Market Share by Region (2021-2026)
Table 19. Global Antibody-radionuclide Conjugates Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Antibody-radionuclide Conjugates Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Antibody-radionuclide Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Antibody-radionuclide Conjugates Market Size Market Share by Country (2021-2026)
Table 23. Americas Antibody-radionuclide Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
Table 25. Americas Antibody-radionuclide Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
Table 27. APAC Antibody-radionuclide Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Antibody-radionuclide Conjugates Market Size Market Share by Region (2021-2026)
Table 29. APAC Antibody-radionuclide Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Antibody-radionuclide Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Antibody-radionuclide Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Antibody-radionuclide Conjugates Market Size Market Share by Country (2021-2026)
Table 33. Europe Antibody-radionuclide Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Antibody-radionuclide Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Antibody-radionuclide Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Antibody-radionuclide Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Antibody-radionuclide Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Antibody-radionuclide Conjugates
Table 39. Key Market Challenges & Risks of Antibody-radionuclide Conjugates
Table 40. Key Industry Trends of Antibody-radionuclide Conjugates
Table 41. Global Antibody-radionuclide Conjugates Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Antibody-radionuclide Conjugates Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Antibody-radionuclide Conjugates Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Antibody-radionuclide Conjugates Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Bayer Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 46. Bayer Antibody-radionuclide Conjugates Product Offered
Table 47. Bayer Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Bayer Main Business
Table 49. Bayer Latest Developments
Table 50. Novartis Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 51. Novartis Antibody-radionuclide Conjugates Product Offered
Table 52. Novartis Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Novartis Main Business
Table 54. Novartis Latest Developments
Table 55. Lantheus Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 56. Lantheus Antibody-radionuclide Conjugates Product Offered
Table 57. Lantheus Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Lantheus Main Business
Table 59. Lantheus Latest Developments
Table 60. Aurobindo Pharma Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 61. Aurobindo Pharma Antibody-radionuclide Conjugates Product Offered
Table 62. Aurobindo Pharma Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Aurobindo Pharma Main Business
Table 64. Aurobindo Pharma Latest Developments
Table 65. Mundipharma Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 66. Mundipharma Antibody-radionuclide Conjugates Product Offered
Table 67. Mundipharma Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Mundipharma Main Business
Table 69. Mundipharma Latest Developments
Table 70. China Isotope & Radiation Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 71. China Isotope & Radiation Antibody-radionuclide Conjugates Product Offered
Table 72. China Isotope & Radiation Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. China Isotope & Radiation Main Business
Table 74. China Isotope & Radiation Latest Developments
Table 75. Curium Pharmaceuticals Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 76. Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
Table 77. Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Curium Pharmaceuticals Main Business
Table 79. Curium Pharmaceuticals Latest Developments
Table 80. Gilead Sciences Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 81. Gilead Sciences Antibody-radionuclide Conjugates Product Offered
Table 82. Gilead Sciences Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Gilead Sciences Main Business
Table 84. Gilead Sciences Latest Developments
Table 85. Clarity Pharmaceuticals Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 86. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
Table 87. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Clarity Pharmaceuticals Main Business
Table 89. Clarity Pharmaceuticals Latest Developments
Table 90. Curasight Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 91. Curasight Antibody-radionuclide Conjugates Product Offered
Table 92. Curasight Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Curasight Main Business
Table 94. Curasight Latest Developments
Table 95. Nordic Nanovector Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 96. Nordic Nanovector Antibody-radionuclide Conjugates Product Offered
Table 97. Nordic Nanovector Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Nordic Nanovector Main Business
Table 99. Nordic Nanovector Latest Developments
Table 100. Philogen Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 101. Philogen Antibody-radionuclide Conjugates Product Offered
Table 102. Philogen Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Philogen Main Business
Table 104. Philogen Latest Developments
Table 105. RadioMedix Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 106. RadioMedix Antibody-radionuclide Conjugates Product Offered
Table 107. RadioMedix Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. RadioMedix Main Business
Table 109. RadioMedix Latest Developments
Table 110. Telix Pharmaceuticals Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 111. Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
Table 112. Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Telix Pharmaceuticals Main Business
Table 114. Telix Pharmaceuticals Latest Developments
Table 115. Orano Med Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 116. Orano Med Antibody-radionuclide Conjugates Product Offered
Table 117. Orano Med Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Orano Med Main Business
Table 119. Orano Med Latest Developments
Table 120. Actinium Pharmaceuticals Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 121. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
Table 122. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Actinium Pharmaceuticals Main Business
Table 124. Actinium Pharmaceuticals Latest Developments
Table 125. Y-mAbs Therapeutics Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 126. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Offered
Table 127. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Y-mAbs Therapeutics Main Business
Table 129. Y-mAbs Therapeutics Latest Developments
Table 130. Fusion Pharmaceuticals Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 131. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
Table 132. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Fusion Pharmaceuticals Main Business
Table 134. Fusion Pharmaceuticals Latest Developments
Table 1. Antibody-radionuclide Conjugates Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Antibody-radionuclide Conjugates Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Beta-emitting
Table 4. Major Players of Targeted Alpha Therapy
Table 5. Antibody-radionuclide Conjugates Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Antibody-radionuclide Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
Table 8. Antibody-radionuclide Conjugates Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Antibody-radionuclide Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
Table 11. Global Antibody-radionuclide Conjugates Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Antibody-radionuclide Conjugates Revenue Market Share by Player (2021-2026)
Table 13. Antibody-radionuclide Conjugates Key Players Head office and Products Offered
Table 14. Antibody-radionuclide Conjugates Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Antibody-radionuclide Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Antibody-radionuclide Conjugates Market Size Market Share by Region (2021-2026)
Table 19. Global Antibody-radionuclide Conjugates Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Antibody-radionuclide Conjugates Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Antibody-radionuclide Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Antibody-radionuclide Conjugates Market Size Market Share by Country (2021-2026)
Table 23. Americas Antibody-radionuclide Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
Table 25. Americas Antibody-radionuclide Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
Table 27. APAC Antibody-radionuclide Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Antibody-radionuclide Conjugates Market Size Market Share by Region (2021-2026)
Table 29. APAC Antibody-radionuclide Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Antibody-radionuclide Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Antibody-radionuclide Conjugates Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Antibody-radionuclide Conjugates Market Size Market Share by Country (2021-2026)
Table 33. Europe Antibody-radionuclide Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Antibody-radionuclide Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Antibody-radionuclide Conjugates Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Antibody-radionuclide Conjugates Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Antibody-radionuclide Conjugates Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Antibody-radionuclide Conjugates
Table 39. Key Market Challenges & Risks of Antibody-radionuclide Conjugates
Table 40. Key Industry Trends of Antibody-radionuclide Conjugates
Table 41. Global Antibody-radionuclide Conjugates Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Antibody-radionuclide Conjugates Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Antibody-radionuclide Conjugates Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Antibody-radionuclide Conjugates Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Bayer Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 46. Bayer Antibody-radionuclide Conjugates Product Offered
Table 47. Bayer Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Bayer Main Business
Table 49. Bayer Latest Developments
Table 50. Novartis Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 51. Novartis Antibody-radionuclide Conjugates Product Offered
Table 52. Novartis Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Novartis Main Business
Table 54. Novartis Latest Developments
Table 55. Lantheus Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 56. Lantheus Antibody-radionuclide Conjugates Product Offered
Table 57. Lantheus Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Lantheus Main Business
Table 59. Lantheus Latest Developments
Table 60. Aurobindo Pharma Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 61. Aurobindo Pharma Antibody-radionuclide Conjugates Product Offered
Table 62. Aurobindo Pharma Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Aurobindo Pharma Main Business
Table 64. Aurobindo Pharma Latest Developments
Table 65. Mundipharma Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 66. Mundipharma Antibody-radionuclide Conjugates Product Offered
Table 67. Mundipharma Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Mundipharma Main Business
Table 69. Mundipharma Latest Developments
Table 70. China Isotope & Radiation Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 71. China Isotope & Radiation Antibody-radionuclide Conjugates Product Offered
Table 72. China Isotope & Radiation Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. China Isotope & Radiation Main Business
Table 74. China Isotope & Radiation Latest Developments
Table 75. Curium Pharmaceuticals Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 76. Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
Table 77. Curium Pharmaceuticals Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Curium Pharmaceuticals Main Business
Table 79. Curium Pharmaceuticals Latest Developments
Table 80. Gilead Sciences Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 81. Gilead Sciences Antibody-radionuclide Conjugates Product Offered
Table 82. Gilead Sciences Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Gilead Sciences Main Business
Table 84. Gilead Sciences Latest Developments
Table 85. Clarity Pharmaceuticals Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 86. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
Table 87. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Clarity Pharmaceuticals Main Business
Table 89. Clarity Pharmaceuticals Latest Developments
Table 90. Curasight Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 91. Curasight Antibody-radionuclide Conjugates Product Offered
Table 92. Curasight Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Curasight Main Business
Table 94. Curasight Latest Developments
Table 95. Nordic Nanovector Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 96. Nordic Nanovector Antibody-radionuclide Conjugates Product Offered
Table 97. Nordic Nanovector Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Nordic Nanovector Main Business
Table 99. Nordic Nanovector Latest Developments
Table 100. Philogen Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 101. Philogen Antibody-radionuclide Conjugates Product Offered
Table 102. Philogen Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Philogen Main Business
Table 104. Philogen Latest Developments
Table 105. RadioMedix Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 106. RadioMedix Antibody-radionuclide Conjugates Product Offered
Table 107. RadioMedix Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. RadioMedix Main Business
Table 109. RadioMedix Latest Developments
Table 110. Telix Pharmaceuticals Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 111. Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
Table 112. Telix Pharmaceuticals Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Telix Pharmaceuticals Main Business
Table 114. Telix Pharmaceuticals Latest Developments
Table 115. Orano Med Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 116. Orano Med Antibody-radionuclide Conjugates Product Offered
Table 117. Orano Med Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Orano Med Main Business
Table 119. Orano Med Latest Developments
Table 120. Actinium Pharmaceuticals Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 121. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
Table 122. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Actinium Pharmaceuticals Main Business
Table 124. Actinium Pharmaceuticals Latest Developments
Table 125. Y-mAbs Therapeutics Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 126. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Offered
Table 127. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Y-mAbs Therapeutics Main Business
Table 129. Y-mAbs Therapeutics Latest Developments
Table 130. Fusion Pharmaceuticals Details, Company Type, Antibody-radionuclide Conjugates Area Served and Its Competitors
Table 131. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Offered
Table 132. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Fusion Pharmaceuticals Main Business
Table 134. Fusion Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Antibody-radionuclide Conjugates Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Antibody-radionuclide Conjugates Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Antibody-radionuclide Conjugates Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Antibody-radionuclide Conjugates Sales Market Share by Country/Region (2025)
Figure 8. Antibody-radionuclide Conjugates Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Antibody-radionuclide Conjugates Market Size Market Share by Type in 2025
Figure 10. Antibody-radionuclide Conjugates in Solid Tumor
Figure 11. Global Antibody-radionuclide Conjugates Market: Solid Tumor (2021-2026) & ($ millions)
Figure 12. Antibody-radionuclide Conjugates in Non Hodgkin Lymphoma
Figure 13. Global Antibody-radionuclide Conjugates Market: Non Hodgkin Lymphoma (2021-2026) & ($ millions)
Figure 14. Global Antibody-radionuclide Conjugates Market Size Market Share by Application in 2025
Figure 15. Global Antibody-radionuclide Conjugates Revenue Market Share by Player in 2025
Figure 16. Global Antibody-radionuclide Conjugates Market Size Market Share by Region (2021-2026)
Figure 17. Americas Antibody-radionuclide Conjugates Market Size 2021-2026 ($ millions)
Figure 18. APAC Antibody-radionuclide Conjugates Market Size 2021-2026 ($ millions)
Figure 19. Europe Antibody-radionuclide Conjugates Market Size 2021-2026 ($ millions)
Figure 20. Middle East & Africa Antibody-radionuclide Conjugates Market Size 2021-2026 ($ millions)
Figure 21. Americas Antibody-radionuclide Conjugates Value Market Share by Country in 2025
Figure 22. United States Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 23. Canada Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 24. Mexico Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 25. Brazil Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 26. APAC Antibody-radionuclide Conjugates Market Size Market Share by Region in 2025
Figure 27. APAC Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
Figure 28. APAC Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
Figure 29. China Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 30. Japan Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 31. South Korea Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 32. Southeast Asia Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 33. India Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 34. Australia Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 35. Europe Antibody-radionuclide Conjugates Market Size Market Share by Country in 2025
Figure 36. Europe Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
Figure 37. Europe Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
Figure 38. Germany Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 39. France Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 40. UK Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 41. Italy Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 42. Russia Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 43. Middle East & Africa Antibody-radionuclide Conjugates Market Size Market Share by Region (2021-2026)
Figure 44. Middle East & Africa Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
Figure 45. Middle East & Africa Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
Figure 46. Egypt Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 47. South Africa Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 48. Israel Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 49. Turkey Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 50. GCC Countries Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 51. Americas Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 52. APAC Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 53. Europe Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 54. Middle East & Africa Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 55. United States Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 56. Canada Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 57. Mexico Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 58. Brazil Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 59. China Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 60. Japan Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 61. Korea Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 62. Southeast Asia Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 63. India Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 64. Australia Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 65. Germany Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 66. France Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 67. UK Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 68. Italy Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 69. Russia Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 70. Egypt Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 71. South Africa Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 72. Israel Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 73. Turkey Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 74. Global Antibody-radionuclide Conjugates Market Size Market Share Forecast by Type (2027-2032)
Figure 75. Global Antibody-radionuclide Conjugates Market Size Market Share Forecast by Application (2027-2032)
Figure 76. GCC Countries Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 1. Antibody-radionuclide Conjugates Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Antibody-radionuclide Conjugates Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Antibody-radionuclide Conjugates Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Antibody-radionuclide Conjugates Sales Market Share by Country/Region (2025)
Figure 8. Antibody-radionuclide Conjugates Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Antibody-radionuclide Conjugates Market Size Market Share by Type in 2025
Figure 10. Antibody-radionuclide Conjugates in Solid Tumor
Figure 11. Global Antibody-radionuclide Conjugates Market: Solid Tumor (2021-2026) & ($ millions)
Figure 12. Antibody-radionuclide Conjugates in Non Hodgkin Lymphoma
Figure 13. Global Antibody-radionuclide Conjugates Market: Non Hodgkin Lymphoma (2021-2026) & ($ millions)
Figure 14. Global Antibody-radionuclide Conjugates Market Size Market Share by Application in 2025
Figure 15. Global Antibody-radionuclide Conjugates Revenue Market Share by Player in 2025
Figure 16. Global Antibody-radionuclide Conjugates Market Size Market Share by Region (2021-2026)
Figure 17. Americas Antibody-radionuclide Conjugates Market Size 2021-2026 ($ millions)
Figure 18. APAC Antibody-radionuclide Conjugates Market Size 2021-2026 ($ millions)
Figure 19. Europe Antibody-radionuclide Conjugates Market Size 2021-2026 ($ millions)
Figure 20. Middle East & Africa Antibody-radionuclide Conjugates Market Size 2021-2026 ($ millions)
Figure 21. Americas Antibody-radionuclide Conjugates Value Market Share by Country in 2025
Figure 22. United States Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 23. Canada Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 24. Mexico Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 25. Brazil Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 26. APAC Antibody-radionuclide Conjugates Market Size Market Share by Region in 2025
Figure 27. APAC Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
Figure 28. APAC Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
Figure 29. China Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 30. Japan Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 31. South Korea Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 32. Southeast Asia Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 33. India Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 34. Australia Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 35. Europe Antibody-radionuclide Conjugates Market Size Market Share by Country in 2025
Figure 36. Europe Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
Figure 37. Europe Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
Figure 38. Germany Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 39. France Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 40. UK Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 41. Italy Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 42. Russia Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 43. Middle East & Africa Antibody-radionuclide Conjugates Market Size Market Share by Region (2021-2026)
Figure 44. Middle East & Africa Antibody-radionuclide Conjugates Market Size Market Share by Type (2021-2026)
Figure 45. Middle East & Africa Antibody-radionuclide Conjugates Market Size Market Share by Application (2021-2026)
Figure 46. Egypt Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 47. South Africa Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 48. Israel Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 49. Turkey Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 50. GCC Countries Antibody-radionuclide Conjugates Market Size Growth 2021-2026 ($ millions)
Figure 51. Americas Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 52. APAC Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 53. Europe Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 54. Middle East & Africa Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 55. United States Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 56. Canada Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 57. Mexico Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 58. Brazil Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 59. China Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 60. Japan Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 61. Korea Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 62. Southeast Asia Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 63. India Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 64. Australia Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 65. Germany Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 66. France Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 67. UK Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 68. Italy Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 69. Russia Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 70. Egypt Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 71. South Africa Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 72. Israel Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 73. Turkey Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
Figure 74. Global Antibody-radionuclide Conjugates Market Size Market Share Forecast by Type (2027-2032)
Figure 75. Global Antibody-radionuclide Conjugates Market Size Market Share Forecast by Application (2027-2032)
Figure 76. GCC Countries Antibody-radionuclide Conjugates Market Size 2027-2032 ($ millions)
